GRI Bio (NASDAQ: GRI) said CEO Marc Hertz was featured in a Virtual Investor “What This Means” segment on February 17, 2026. Hertz discussed additional positive Phase 2a data in idiopathic pulmonary fibrosis (IPF), highlighting biomarker improvements tied to fibrosis and lung repair.
The segment is available via the company’s virtual investor content library for investors seeking details on the biomarker results and clinical implications.
Loading…
Loading translation…
On the day this news was published, GRI declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
$2.31 Last Close
Volume Volume 32,536 vs 20-day average 970,840 (relative volume 0.03x) indicates limited trading interest ahead of this CEO interview segment. low
Technical Shares at $2.31 are trading below the 200-day MA of $37.89 and sit far beneath the $311.36 52-week high, closer to the $2.10 52-week low.
Momentum scanner shows mixed biotech peer moves: JAGX down 3.89%, ONCO down 3.59%, and APVO up 3.73%. Sector summary notes 2 peers moving together with median move -3.7%, suggesting broader biotech dynamics alongside this company-specific communication update.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Investor webinar | Positive | -17.1% | Announced participation in Webull-hosted Corporate Connect virtual conference. |
| Feb 04 | Earnings & update | Positive | +1.5% | Reiterated 2025 results, raised $6.5M, and highlighted positive Phase 2a data. |
| Jan 28 | Clinical data update | Positive | -22.7% | Released new Phase 2a RNA-seq data for GRI-0621 in IPF showing fibrosis signals. |
| Jan 26 | Patent issuance | Positive | -1.5% | Announced new U.S. composition-of-matter patent for novel compound structures. |
| Jan 21 | Reverse stock split | Negative | -4.2% | Approved 1-for-28 reverse split to address Nasdaq bid-price compliance. |
Pattern Detected
Recent positive clinical, IP, and investor-relations updates have often coincided with flat to negative next-day price reactions, while balance sheet strengthening and structural actions like the reverse split saw more moderate moves.
Recent Company History
Over the last month, GRI Bio reported multiple milestones: a 1-for-28 reverse split and related Nasdaq compliance steps, new U.S. composition-of-matter patent protection, and additional positive Phase 2a IPF data with gene-expression and biomarker signals. It also reiterated 2025 financials and strengthened its cash position, plus participated in a Webull-hosted investor webinar. Today’s Virtual Investor segment revisits those positive Phase 2a IPF results and biomarker data, extending the company’s recent outreach around its clinical story.
$250,000,000 registered capacity
An effective Form S-3 shelf filed on 2026-01-29 permits GRI Bio to offer up to $250,000,000 in various securities over time. A related 424B5 filing supports an at-the-market program of up to $60,000,000, of which $12,639,002.84 in shares had already been sold under the existing program, indicating active use of this financing flexibility.
This announcement underscores GRI Bio’s strategy of spotlighting its additional positive Phase 2a IPF and biomarker data via a Virtual Investor segment featuring the CEO. Recent history includes clinical readouts, patent strengthening, a reverse split, and balance-sheet updates. Investors may focus on how these Phase 2a results evolve into later-stage trials, the pace of capital raising under the $250,000,000 shelf and ATM, and the company’s ability to address going-concern and listing risks highlighted in recent filings.
natural killer t medical
“advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators”
Natural killer T cells are a small, specialized group of immune cells that act like a hybrid between frontline soldiers and intelligence agents: they can directly attack abnormal cells and also send signals that shape broader immune responses. They matter to investors because therapies that target or harness these cells are a growing area in cancer and autoimmune drug development, affecting a product’s potential effectiveness, safety profile, clinical trial design and regulatory approval prospects.
nkt cell modulators medical
“pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of”
NKT cell modulators are therapies or compounds that adjust the activity of natural killer T cells, a type of immune cell that helps control infections, cancer, and inflammation. Think of them like a thermostat for part of the immune system: they dial responses up or down to improve disease control while trying to avoid harmful side effects. Investors watch these drugs because their success in clinical trials and safety profile can drive regulatory approval, market size, and company valuation.
idiopathic pulmonary fibrosis medical
“additional positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), including”
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
biomarker medical
“including a series of compelling biomarker results that demonstrate improvements”
A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.
AI-generated analysis. Not financial advice.
Access the “What This Means” segment here
LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment.
As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important insights from the Company’s recently reported additional positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), including a series of compelling biomarker results that demonstrate improvements in key drivers of fibrosis and lung repair.
The “What This Means” segment can be accessed here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What did GRI (GRI) CEO Marc Hertz discuss in the Feb 17, 2026 Virtual Investor segment?
He discussed additional positive Phase 2a IPF data and related biomarker improvements. According to the company, the segment highlights biomarker results showing improvements in drivers of fibrosis and lung repair from the recent trial data.
Where can investors access the GRI (GRI) “What This Means” virtual segment from Feb 17, 2026?
The virtual segment is available through the company’s investor content channels. According to the company, investors can access the “What This Means” video via the GRI Bio investor website or virtual investor library.
What specific clinical findings did GRI (GRI) highlight about its IPF Phase 2a study?
GRI highlighted a series of biomarker results indicating improvements in fibrosis and lung repair drivers. According to the company, these biomarker changes accompanied the additional positive Phase 2a readouts reported recently.
Does the Feb 17, 2026 GRI (GRI) segment provide new financial guidance or earnings information?
No, the segment focused on clinical data and biomarker results, not financial guidance. According to the company, the presentation reviewed Phase 2a clinical insights rather than financial metrics or guidance.
What should investors look for next after GRI’s Feb 2026 Phase 2a IPF update (GRI)?
Investors should watch for formal clinical readouts and regulatory milestones tied to IPF development. According to the company, the virtual segment contextualizes biomarker improvements ahead of further trial updates or filings.
